19 February 2021
Visiongain has published a new report on Enteric Soft Gel Capsules Market Report 2021-2031: Forecasts By Product Type (Gelatin Enteric Soft Gel Capsules, and Non-Gelatin Enteric Soft Gel Capsules), By Application (Pharmaceuticals, and Medical and Health Supplements), By Patient Demographics (Geriatric, Adult, and Pediatric), By End User (Hospitals, Homecare, Specialty Clinics, and Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, and Online Pharmacies) PLUS Profiles of Leading Manufacturing Companies and Regional and Leading National Market Analysis. PLUS COVID-19 Recovery Scenarios.
Global Enteric Soft Gel Capsules market was valued at US$ xx Million in 2020 and is projected to reach at a market value of US$ xx Million by 2031. North America dominated the global Enteric Soft Gel Capsules market and is projected to witness CAGR of XX% during the first half of the forecast period i.e. 2021 to 2031.
COVID-19 Impact on Enteric Soft Gel Capsules Market
COVID-19 impact through different recovery models such as V-shaped, U-shaped, W-shaped, and L-shaped; has been taken into consideration while estimating and forecasting the Enteric Soft Gel Capsules market. Different recovery scenarios are also included in the report for all the segments and regions/nation. The recovery scenarios based on which market has been forecasted and analysed herein the report are mentioned below:
Growing Demand for Omega-3 Supplements around the World
Demand for omega-3 supplements is increasing due to increasing awareness regarding the importance of administration of preventive medicines and soft gel-based health supplements in developing and developed countries. With increasing demand of omega-3 supplements by hospitals, homecare, specialty clinics, and among others it is expected that, many of the manufacturers will launch their product portfolios in companion enteric soft gel capsules in the order to increase their revenue generation due to this reason the factor is working as a driver for the enteric soft gel capsules market.
Increasing Geriatric Population around the World
People are at a high risk of cognitive decline in old age due to reduced immune system and bone health, muscle performance. Elder people who are at high risk require to take enteric soft gel capsules (dietary supplementation) which have substantial benefits in reduction of cognitive decline risk in older people by maintaining preventing the loss of muscle mass and bone health and function associated with physiological ageing, immune function. Over the last few years, the number of geriatric populations is increasing very fast around the world. The region is facing rapid increase in the geriatric population. For instance: According to the United Nations, Department of Economic and Social Affairs, Population division geriatric population (persons aged 65 or over) was 702.9 million in 2019. Continuous increase in the number of the geriatric population around the world is also increasing demand for enteric soft gel capsules around the world.
Growing Awareness Regarding Consumption of Preventive Medicines
Awareness programs for consumption of preventive medicines from the governments, regulatory authorities, national & international organizations around the world is increasing very rapidly as compared to the last few years. Preventive care and medication always remain the matter of concern and research as it's been related to human life and survivors. Awareness programs are focusing to increase the awareness related to preventive care and medication to reduce mortality rate related to undiagnosed or untreated patients and to strengthen people’s immune systems. These awareness programs are expected to increase the demand of the enteric soft gel capsules in the forecasted periods.
Top companies (BASF SE, Catalent, Inc., Colorcon, Inc., and Fuji Capsules Co., Ltd.) constitute more than XX% share of the global Enteric Soft Gel Capsules market. Other companies profiled in the report include: Procaps, NOW Foods Inc., Thermo Fisher Scientific, Inc. (Patheon), Sirio Pharma Co., LTD, Super Spectrim, Osmotica Pharmaceuticals plc. (Trigen Laboratories, Inc.)) among others Some of the key developments are listed below:
● In 2020, BIOSALMA has launched Omega-3 Pure and Natural product, which is fully certified to both MSC and ASC standards. The product is World’s First MSC and ASC Certified Omega-3 Supplements. The launch will help the company widen revenue generation from a market focused product portfolio.
Notes for Editors
If you are interested in a more detailed overview of this report, please send an e-mail to email@example.com or call her on +44 (0) 20 7549 9987.
Visiongain is one of the fastest-growing and most innovative independent media companies in Europe. Based in London, UK, Visiongain produces a host of business-to-business reports focusing on the automotive, aviation, chemicals, cyber, defence, energy, food & drink, materials, packaging, pharmaceutical and utilities sectors.
Visiongain publishes reports produced by analysts who are qualified experts in their field. Visiongain has firmly established itself as the first port of call for the business professional who needs independent, high-quality, original material to rely and depend on.
We predict strong revenue growth through to 2031. Our work identifies which organizations hold the greatest potential. Discover their capabilities, progress, and commercial prospects, helping you stay ahead.
29 July 2021
Over the last few years, Direct-to-Patient has gained widespread attention. DTP companies offer their customers, who are patients, in this case, all kinds of services.
21 July 2021
Rising geriatric population, increasing prevalence of chronic and infectious diseases, escalating investment in drug R&D by biopharmaceutical companies, rising demand for advanced drug delivery technologies for chronic treatment are some of the major factors that drive the growth of the global drug delivery technologies market.
20 July 2021
Pharma services companies are widening their service offerings (either organically or inorganically through M&A) to become full-service providers, simplifying their customers’ operations and gaining the maximum share of their outsourcing budgets, driven by the willingness of pharma to reduce the number of outsourcers they use.